|
|
|
|
Thursday, May 7, 2020
TherapeuticsMD Inc. (TXMD)
Focusing on Annovera and Imvexxy Commercialization
(current) TherapeuticsMD, Inc. is a women’s healthcare company focused on developing and commercializing products targeted exclusively for women. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD’ and BocaGreenMD’ brands. The company is currently developing advanced hormone therapy pharmaceutical products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. It is also evaluating various other potential indications for our hormone technology, including oral contraception, preterm birth, vulvar and vaginal atrophy, and premature ovarian failure.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Q1 2020 earnings release. The company reported first-quarter earnings yesterday. Total revenues from marketed products reached $12.3 mm, EBITDA was ($50.7 mm) and EPS was ($0.21).
Greater patient demand for Annovera. In Q1 2020, Annovera net sales were $2.3 million showing a reduction (from $5.8 million in Q4 2019), primarily attributed to lower wholesale orders by the distributors. Total prescriptions sold to patients doubled in Q1 2020. Prescription numbers represent a positive trajectory and greater patient demand. Large scale consumer campaign is now expected to…
Click to get the full report.
This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.
